Eckelman Brendan P. 4
4 · Inhibrx, Inc. · Filed Mar 15, 2024
Insider Transaction Report
Form 4
Inhibrx, Inc.INBX
Eckelman Brendan P.
DirectorChief Scientific Officer10% Owner
Transactions
- Exercise/Conversion
Stock Option (right to buy)
2024-03-13$35.33/sh−1,898$67,062→ 9,177 totalExercise: $33.63Exp: 2031-01-15→ Common Stock (1,898 underlying)
Footnotes (1)
- [F1]Twenty-five percent (25%) of the total shares subject to the stock option became exercisable on January 15, 2022, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter.